Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E33.55 EPS (ttm)1.00 Insider Own0.04% Shs Outstand6.07B Perf Week3.93%
Market Cap204.02B Forward P/E12.07 EPS next Y2.79 Insider Trans-1.32% Shs Float6.06B Perf Month7.14%
Income6.18B PEG5.38 EPS next Q0.67 Inst Own71.70% Short Float0.57% Perf Quarter6.27%
Sales53.24B P/S3.83 EPS this Y6.70% Inst Trans0.01% Short Ratio1.36 Perf Half Y-2.53%
Book/sh10.43 P/B3.22 EPS next Y8.96% ROA- Target Price37.48 Perf Year18.33%
Cash/sh- P/C- EPS next 5Y6.24% ROE- 52W Range27.69 - 36.35 Perf YTD4.56%
Dividend1.28 P/FCF- EPS past 5Y1.32% ROI- 52W High-7.50% Beta0.98
Dividend %3.81% Quick Ratio- Sales past 5Y- Gross Margin76.60% 52W Low21.42% ATR0.49
Employees97900 Current Ratio- Sales Q/Q-3.00% Oper. Margin- RSI (14)74.56 Volatility1.58% 1.41%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.37 Prev Close33.62
ShortableYes LT Debt/Eq- EarningsJan 31 BMO Payout102.50% Avg Volume25.31M Price33.62
Recom2.40 SMA205.39% SMA504.80% SMA2001.96% Volume34,698,022 Change0.00%
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Feb-19-17 07:54AM  A Billionaire Recently Bought Pfizer Stock -- and So Did I at Motley Fool
Feb-18-17 05:41PM  Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc. at Motley Fool
07:01AM  The Best Investments for an IRA at Motley Fool
05:53AM  Roche says Phase II trial supports twin treatment for kidney cancer Reuters
Feb-17-17 06:41PM  Momenta Pharma shares halted as drug application hits speed bump at MarketWatch
05:01PM  Trade or fade this week's Dow winners?
04:31PM  AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink
12:00PM  New Data in Crohns Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a Business Wire
08:13AM  Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
07:21AM  Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ
07:05AM  Santhera opens Mass. office as local Duchenne ecosystem grows at
Feb-16-17 06:55PM  Why This Billionaire Just Shelled Out $1.1 Billion on 4 Drug Stocks at Motley Fool
03:57PM  3 Dividend Stocks That Prove Boring Is Beautiful at Motley Fool
12:06PM  David Tepper Invests Heavily in Pharma in 4th Quarter
11:41AM  How Bristol-Myers Squibb and Pfizer Are Winning a Big Brawl in Blood Thinners at Motley Fool
10:46AM  Procter & Gamble, Pfizer Lead Market Gains
09:19AM  Here Comes Pfizer's Powerful Breakout
09:00AM  Washington University to collaborate with Pfizer on drug discovery at
08:16AM  Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone at MarketWatch
08:00AM  Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab) Business Wire
Feb-15-17 04:01PM  Pfizer, Cisco Push DJIA Higher Wednesday
03:03PM  5 Ways Allergan Can Keep Up Momentum
02:18PM  Tepper's Appaloosa triples stake in Allergan
12:38PM  Bristol-Myers: Don't Bet on a Pfizer Acquisition at
09:25AM  4 High-Yield Dividend Stocks You Don't Have to Babysit at Motley Fool
08:06AM  Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip
Feb-14-17 05:32PM  David Tepper Increases Wagers on Drug Companies at The Wall Street Journal
03:33PM  Bristol-Myers Squibb: Takeover Target? at
12:49PM  Investing Rookie? Start With These 3 Stocks at Motley Fool
10:45AM  Three Stocks To Buy For Valentines Day at Insider Monkey
09:30AM  The Zacks Analyst Blog Highlights: Boeing, Pfizer, Goldman Sachs, NVIDIA and Twitter
12:25AM  Luxury, lingerie and...Viagra?
Feb-13-17 05:11PM  Allergan To Acquire ZELTIQ in $2.47 Billion Deal, ZELTIQ Shares Pop 13%
02:19PM  Q4 Scorecard & Analyst Reports for Pfizer, Boeing & Goldman Sachs
02:05PM  Lets just call it an American Rally, OK? at MarketWatch
08:00AM  3 Stocks You Can Still Buy With the Market at Record Highs at Motley Fool
Feb-12-17 10:10PM  US issuers rush to sell Formosa bonds before rule change Reuters
Feb-10-17 12:00PM  Is More Downside Ahead For Teva Pharmaceutical? at
11:09AM  Actinium Pharmaceuticals (ATNM) has Considerable Potential in 2017
08:35AM  Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?
Feb-09-17 12:00PM  Academics call time on $100,000 cancer drugs Reuters
08:50AM  10 Best Dividend-Paying Stocks for 2017 at Kiplinger
08:30AM  Relationship Expert Teams Up with Pfizer to Address Intimacy and Relationship Issues for People Living with Chronic Diseases Business Wire
Feb-08-17 06:54PM  Pfizer Builds Consumer Apps to Improve Patient Care at The Wall Street Journal
02:30PM  Pfizer Inc. Value Analysis (NYSE:PFE) : February 8, 2017
02:10PM  3 Greater Washington biotech execs sign industry letter opposing the Trump travel ban at
01:30PM  4 Dow Stocks Every Retiree Should Own at Kiplinger
01:28PM  Gilead: Where's the Bottom? at
09:48AM  [$$] Sanofi points to lower profit for 2017 at Financial Times
Feb-07-17 12:28PM  Pfizer Inc. (PFE) And Citibank To Work Together On $5 Billion Share Repurchase Program at Insider Monkey
07:22AM  Pfizer Inc. breached its 50 day moving average in a Bullish Manner : PFE-US : February 7, 2017
Feb-06-17 12:56PM  Pfizer CEO: 'Misinformation About Drug Pricing Is Far Greater Than I've Ever Seen'
09:55AM  Q4 Earnings Faring Well for Pharma ETFs
09:30AM  The Zacks Analyst Blog Highlights: Apple, Exxon Mobil, Merck, Pfizer and Intel
08:15AM  Blog Coverage Pfizer Signs Agreement with Citibank to Repurchase $5 Billion Worth of Shares Accesswire
07:45AM  ICU Medical Completes the Acquisition of Hospira Infusion Systems from Pfizer GlobeNewswire
Feb-04-17 06:41AM  Pfizer's New Biosimilar Is Off and Running at Motley Fool
Feb-03-17 01:00PM  MACD: Learn to Recognize Trade Setups
11:19AM  Pfizer Is Returning Even More Cash to Shareholders
10:50AM  Pfizer Inc. (PFE)s Breast Cancer Drug Too Expensive: Says NICE at Insider Monkey
10:36AM  Novartiss Valuation after the 4Q16 Results
09:48AM  What Alicia Keys and Daft Punk are bringing home after the Grammys at MarketWatch
08:37AM  Stock Futures Hold Higher After U.S. Economy Adds 227,000 Jobs
08:16AM  Pfizer to buyback $5 billion of its common stock at MarketWatch
08:10AM  Pfizer Commences $5 Billion Accelerated Share Repurchase Business Wire
06:54AM  Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling
Feb-02-17 07:09PM  UK agency says Pfizer breast cancer drug too expensive Reuters
03:13PM  PFE May Reportedly Sell Part of its Portfolio at Investopedia
01:03PM  Pfizer hires JPMorgan to weigh sale of some drugs: Bloomberg
12:59PM  Pfizer hires JPMorgan to weigh sale of some drugs - Bloomberg
12:03PM  Pfizer Said to Hire JPMorgan to Weigh $2 Billion Portfolio Sale at Bloomberg
11:21AM  The 10 cheapest, fastest-growing and most beloved Dow stocks at MarketWatch
10:53AM  Ignore Gilead Sciences Inc.: Here Are 2 Better Stocks at Motley Fool
09:53AM  US Market Indexes Regain Some of Their Losses on Wednesday
09:52AM  Merck (MRK) Tops Q4 Earnings; Pharmaceutical Sales Down
07:00AM  3 Pharmaceutical Stocks With Bigger Dividends Than Johnson & Johnson at Motley Fool
03:55AM  [$$] Reckitt Benckiser in talks over $16.7bn baby milk deal at Financial Times
Feb-01-17 04:00PM  5 Things Pfizer's Management Wants You to Know at Motley Fool
01:10PM  How to Play Pfizer's Fourth-Quarter Results With ETFs
08:14AM  Top Healthcare Stocks to Buy in 2017 at Motley Fool
12:51AM  [$$] Trumps Criticism of Imports Adds to Drugmakers Headaches at The Wall Street Journal
Jan-31-17 11:58PM  [$$] Trump Inauguration Drew More Than 18 Corporate Donors at The Wall Street Journal
10:57PM  [$$] Pfizer Revenue Falls As Full-Year Sales Seen Below Wall Street Estimates at The Wall Street Journal
09:53PM  Edited Transcript of PFE earnings conference call or presentation 31-Jan-17 3:00pm GMT
08:49PM  [$$] Trumps Criticism of Imports Adds to Drugmakers Headaches at The Wall Street Journal
06:47PM  [$$] Trump's Criticism of Imports Adds to Drugmakers' Headaches at The Wall Street Journal
05:59PM  Final Trade: FDX, FCX & more
05:08PM  Pfizer swings to 4Q profit after rough year, hikes 2017 view
04:21PM  Pfizer's 3 Fastest-Growing Drugs at Motley Fool
04:17PM  Fmr. Onyx CEO: Responsibility to find and research cures ...
04:11PM  Pfizer Reports Lagging Q4 EPS; Rebounds On Trump Commentary
03:37PM  Pfizer Needs to Keep Dealing at Bloomberg
03:21PM  [$$] Trump Tells Pharmaceutical CEOs He Wants Prices Down at The Wall Street Journal
03:01PM  Pfizer CEO says no need to alter its drug pricing practices Reuters
02:12PM  Pfizer Shares Look Undervalued
02:05PM  Pfizer Still Looking For Growth at Investopedia
01:24PM  Early movers: UAA, XOM, UPS, MA, LLY, HOG, PFE & more at CNBC
12:44PM  7 Things You Might Have Missed in Pfizer's Q4 Earnings Slip at Motley Fool
11:29AM  Healthcare Names Rally as Pharma Meets with Trump at Investopedia
10:40AM  S&P 500 Falls for a Fourth Day as 'Rose-Tinted Glasses' of Trump Presidency Come Off
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, Transgene S.A., Edelris SAS, IGNITE Immunotherapy Inc., and AbCellera Biologics Inc.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 07Option Exercise25.8730,000776,100167,687Dec 08 09:48 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 09Sale33.0010,000330,000112,087Nov 10 07:44 PM
BOURLA ALBERTGroup PresidentNov 04Option Exercise24.9920,000499,800149,199Nov 07 05:58 PM
BOURLA ALBERTGroup PresidentNov 04Sale30.0518,390552,530130,809Nov 07 05:58 PM
HILL CHARLES HExecutive Vice PresidentNov 03Option Exercise21.0353,9181,133,896115,033Nov 07 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 02Option Exercise21.0332,545684,421122,087Nov 04 04:36 PM
DAMELIO FRANK AExecutive Vice PresidentMay 26Option Exercise24.43100,0002,443,000472,994May 27 11:03 AM
DAMELIO FRANK AExecutive Vice PresidentMay 26Sale34.49100,0003,449,115372,994May 27 11:03 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Option Exercise25.8786,0002,224,820271,663May 26 10:07 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Sale33.9786,0002,921,147185,663May 26 10:07 AM
YOUNG JOHN DGroup PresidentMay 10Option Exercise25.8741,7001,078,779200,399May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Option Exercise24.43192,0004,690,560564,994May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Sale33.66192,0006,462,579372,994May 11 06:04 PM
YOUNG JOHN DGroup PresidentMay 10Sale33.5341,7001,398,277158,699May 11 06:04 PM
READ IAN CChairman & CEOMay 09Option Exercise25.74275,0007,078,2501,471,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Option Exercise22.2823,884532,136199,735May 11 04:35 PM
HILL CHARLES HExecutive Vice PresidentMay 09Sale33.8429,6001,001,65160,828May 11 04:35 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Sale33.7167,8842,288,669131,851May 11 04:35 PM
READ IAN CChairman & CEOMay 09Sale33.80275,0009,295,0391,196,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 05Option Exercise22.2856,0161,248,036231,867May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 05Sale33.7156,0161,888,144175,851May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Option Exercise22.2820,100447,828195,951May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Sale33.8720,100680,762175,851May 06 09:51 AM
DAMELIO FRANK AExecutive Vice PresidentMay 03Sale33.6587,0792,930,208372,994May 05 05:27 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541274,756Feb 26 03:05 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 24Option Exercise18.9062,4531,180,362140,772Feb 26 03:05 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9018,984358,79889,467Feb 26 03:05 PM
READ IAN CChairman & CEOFeb 24Option Exercise18.90584,11211,039,7172,030,151Feb 26 03:05 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541263,151Feb 26 03:05 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9052,570993,573188,679Feb 26 03:05 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9034,171645,832210,943Feb 26 03:05 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90210,2803,974,292622,467Feb 26 03:05 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90210,2803,974,292577,902Feb 26 03:05 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9078,8551,490,360149,135Feb 26 03:05 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9019,188362,65366,048Feb 26 03:05 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9034,171645,832149,482Feb 26 03:05 PM
BOURLA ALBERTGroup PresidentFeb 24Option Exercise18.9030,666579,587144,675Feb 26 03:03 PM